To fund initiatives that advance care, research, education, and awareness for underfunded and rare cancers—with an early focus on gynecologic (GYN) cancers such as endometrial/uterine serous carcinoma—so that every cancer patient has access to support, treatment options, and research.
The Laughlin Family Foundation for Rare Canc has built its recent giving around rare gynecologic and endometrial cancer research, including repeated $100,000 support for Johns Hopkins in Baltimore for gynecologic oncology and medical research. Its grantmaking is explicitly tied to care, research, education, and awareness for underfunded and rare cancers, with an early emphasis on endometrial and uterine serous carcinoma. That focus shows up in both institutional and young-investigator support. In one 2024 award, the foundation gave $55,000 to the Foundation for Women's Cancer in Chicago for a research grant for high-grade uterine cancer, reflecting its use of partner organizations to move disease-specific research forward. The foundation also supports precision-medicine and clinical-research work aimed at rare and aggressive uterine cancers, including projects connected to screening, early detection, and novel treatment strategies. Across the grants on file, the pattern is consistent: the foundation concentrates on cancers where research funding is more limited and directs its support toward projects that combine research, education, and patient impact.
In gynecologic oncology, the foundation has supported research and education aimed at rare gynecologic cancers, including endometrial, ovarian, cervical, fallopian, vaginal, and vulvar cancers. A 2024 grant to Johns Hopkins University was designated to support gynecologic oncology research. For early-career research, the foundation uses Young Investigators grants, including a $55,000 award through the Foundation for Women's Cancer for high-grade uterine cancer. It also funds precision-medicine work for rare endometrial cancers; one grant supported the Endometrial Cancer Precision Medicine Center framework focused on screening, early detection, and novel treatment strategies. The foundation's program language also includes awareness, which places research grants alongside education-oriented support.
Typical awards cluster tightly around the middle of the foundation's distribution: p25 is $77,500, median is $100,000, and p75 is $100,000. That indicates a small set of standardized grant sizes rather than a broad spread. The recent grants on file show repeat support for the same institutional partners across consecutive years, including Johns Hopkins University in 2023 and 2024. The foundation is a public charity, does not fund individuals, and does not make program-related investments. Its programs are structured and partner-based; the listed grant programs do not accept unsolicited applications.
$155K
$195K
$364K
$378K
Most grants fall between $78K and $100K, with a median of $100K.
25th Percentile
$78K
Median
$100K
75th Percentile
$100K
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Giving is regional, with recipients concentrated in the United States. Maryland accounts for 67% of grants, and the recent grants list includes Baltimore as a repeated recipient city through Johns Hopkins University and Johns Hopkins University Medical School. Outside Maryland, Chicago appears in the recent grants through the Foundation for Women's Cancer. The top state by grant count is Illinois, showing that the foundation's highest-volume giving state is not the same as its headquarters state.
Its stated focus is rare cancers, with an early emphasis on gynecologic cancers such as endometrial and uterine serous carcinoma. Active programs also reference rare gynecologic cancers, high-grade uterine cancer, precision medicine, screening, early detection, and cancer education.
Yes. One active program is a Young Investigators Research Grant for Rare Gynecologic / Endometrial Cancer Research. The recent grants also include a $55,000 award through the Foundation for Women's Cancer for a research grant for high-grade uterine cancer.
The grant-size profile is concentrated: p25 is $77,500, the median is $100,000, and p75 is $100,000. Recent awards on file include two $100,000 grants and one $55,000 grant.
No. The listed active grant programs are marked as not accepting unsolicited applications, indicating that support is structured through the foundation's own program and partnership channels.
No. The data show support for both institutional research settings and partner organizations. Recent grants include Johns Hopkins University in Baltimore and the Foundation for Women's Cancer in Chicago, alongside program descriptions that mention academic medical centers and research-education partnerships.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $100,000 | 2025 | TO SUPPORT GYNECOLOGIC ONCOLOGY RESEARCH |
| FOUNDATION FOR WOMEN'S CANCER | CHICAGO, IL | $55,000 | 2025 | RESEARCH GRANT FOR HIGH GRADE UTERINE CANCER |
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $100,000 | 2024 | TO SUPPORT GYNECOLOGIC ONCOLOGY RESEARCH |
| FOUNDATION FOR WOMEN'S CANCER | CHICAGO, IL | $55,000 | 2024 | RESEARCH GRANT FOR HIGH-GRADE UTERINE CANCER |
| JOHNS HOPKINS UNIVERSITY MEDICAL SCHOOL | BALTIMORE, MD | $100,000 | 2023 | MEDICAL RESEARCH |
MEDICAL RESEARCH